Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy
Haleigh BehrmanDr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC. Read more
Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC
Nathan PettengillResearch team led by Dr. Shun Lu presents aumolertinib with chemotherapy as an additional first-line treatment option during the 2025 AACR Annual Meeting. Read more
A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going
Haleigh BehrmanPioneer in SCLC research Dr. John D. Minna reflected on four decades of advancements in the field during his keynote address at the 2025 Hot Topics in SCLC. Read more
A Real Tail in These Curves: A Look at Advances and Future Directions in SCLC
Haleigh BehrmanDuring a recent address at SCLC 2025, Dr. Charles Rudin discussed the progress being made in reducing the incidence of small cell lung cancer and in treating it. Read more
COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities
Nathan PettengillDr. Nicolas Girard recently presented data that shows prophylactic treatment with oral and topical antibiotics and ceramide-based moisturizer significantly reduced adverse skin events. Read more
Savolitinib Plus Osimertinib Offers Hope for Addressing Resistance, Progression
Nathan PettengillDr. Myung-Ju Ahn said recent data from SAVANNAH show the combination produced a meaningful and durable response in patients whose cancer progressed after osimertinib. Read more
Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy
Haleigh BehrmanDrs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress. Read more
Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award
Nathan PettengillDuring his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology. Read more
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?
Haleigh BehrmanDuring a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies. Read more
With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma
Haleigh BehrmanLacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more